172@29@17@244!~!172@29@0@53!~!|news|business|companies|first-batch-of-ciplas-remdesivir-leaves-contract-manufacturers-site-in-daman-5519711.html!~!|controller|infinite_scroll_article.php
Moneycontrol
Financial Freedom Offer: Subscribe to Moneycontrol Pro and grab benefits worth ₹15,000/-
Last Updated : Jul 08, 2020 09:33 PM IST | Source: Moneycontrol.com

First batch of Cipla's Remdesivir leaves contract manufacturer's site in Daman

Sovereign Pharma has the capacity to scale up production up to 95,000 vials per month

The first batch of Cipla's Remdesivir has left the manufacturing site of Sovereign Pharma, the Daman-based company that was contracted by the former to formulate Remdesivir into finished dosages.

Remdesivir is used in the treatment of hospitalised novel coronavirus, or COVID-19, patients who are on oxygen.

Sovereign Pharma didn't disclose the number of vials that it has shipped, but the management said its second batch is ready to be shipped on July 8. The company has the capacity to scale up production to 95,000 vials per month.

Close

Cipla is among the six Indian generic pharma manufacturers that have signed non-exclusive voluntary licencing agreements with Gilead Sciences for its patented drug Veklury (Remdesivir). The management, in turn, has signed a contract manufacturing agreement with BDR Pharmaceuticals, who have further transferred the formulation technology for manufacturing and packaging of the generic drug to Sovereign Pharma.

Cipla's Remdesivir, to be sold under brand name Cipremi, is the most anticipated in the market given the severe shortage of the drug, even as people continue to fall prey to COVID-19.

Moneycontrol reported here about the shortage of Remdesivir and its diversion into the black market where it is sold up to six times of Hetero's price of Rs 5,400.

Cipla has priced the drug at Rs 4,000 per vial, almost 25 percent cheaper than Hetero's Covifor.

Remdesivir has been recommended for five days, 200 mg IV (intravenous) on day one followed by 100 mg IV daily for four days.

Rishad Dadachanji, Director, Sovereign Pharma, said, “Since last month, we have been constantly manufacturing Remdesivir. At our current capacity, we can supply 50,000 to 95,000 pieces of the injectable per month. We know how critical the situation is, especially with the pandemic still spreading across the country. Hence, we are in constant touch with all our clients and ready to cater to any of their requirements with utmost priority.”

Established in 2003 as a Contract Manufacturing Organisation (CMO) to produce high-quality injectables for pharmaceutical companies worldwide, Sovereign Pharma now produces 350 million pieces each year. Going by the number of doses, it sells over 1 billion injections every year.

Remdesivir is known for successfully reducing the virus load in coronavirus patients and has been going through tests for a specific treatment for COVID-19. It has been authorised for emergency use or severe cases in several countries, including India.
First Published on Jul 7, 2020 08:06 pm
Sections